Tufts Medical Center, Department of Dermatology, 800 Washington Street, Box 114, Boston, MA 02111, USA.
Expert Opin Drug Saf. 2013 Sep;12(5):757-65. doi: 10.1517/14740338.2013.808330. Epub 2013 Jun 8.
The biologic, Ustekinumab (Stelara®, Centocor, Inc., Malvern, PA, USA), is a fully human monoclonal antibody with a high affinity for the shared p40 subunit of interleukins 12 and 23 (IL-12 and IL-23). Approved for use in treating moderate-to-severe psoriasis in 2009, there has been considerable interest in the long-term safety of ustekinumab.
This review discusses the use of ustekinumab in the treatment of psoriasis and its potential to be an effective and well-tolerated therapy. A literature search was performed for articles published through April 2013 to identify any safety concerns.
Our results indicate that ustekinumab has demonstrated higher efficacy rates as compared to traditional therapies; and with a favorable dosing schedule and stable safety profile, patients with recalcitrant disease will now have another option for treatment.
生物制剂乌司奴单抗（喜达诺®，Centocor，Inc.，美国马文）是一种与人源高度同源的单克隆抗体，对白细胞介素 12 和 23（IL-12 和 IL-23）的共同 p40 亚单位具有高亲和力。乌司奴单抗于 2009 年被批准用于治疗中重度银屑病，其长期安全性引起了广泛关注。
本综述讨论了乌司奴单抗在治疗银屑病中的应用及其作为一种有效且耐受性良好的治疗方法的潜力。我们通过检索截至 2013 年 4 月发表的文章，以确定任何安全性问题。
我们的结果表明，与传统疗法相比，乌司奴单抗显示出更高的疗效；并且由于其具有良好的给药方案和稳定的安全性，顽固疾病患者现在将有另一种治疗选择。
